The global targeted therapeutics market size is expected to reach around US$ 83.8 billion by 2030 from US$ 67 billion in 2020 and is expected to grow at an impressive double-digit rate of 2.4% from 2021 to 2030.
The study includes drivers and restraints of this market. The study provides an analysis of the global targeted therapeutics market for the period 2017-2030, wherein 2021 to 2030 is the forecast period and 2020 is considered as the base year.
We customize your report according to your research need. REQUEST CUSTOMIZED COPY OF REPORT (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/customization/1358
Targeted therapeutics is the treatment of diseases using drugs that targets the cancer cells and blocks the proliferation of such cells without damaging normal cells. The growing burden of critical diseases such as cancer, leukemia, lymphoma, and muscular degeneration are the major factors that boost the adoption of targeted therapeutics among the global population.
According to the International Agency for Research on Cancer, in 2020, around 19.3 million new cancer cases and 10 million cancer deaths were reported across the globe. The global cancer cases are estimated to grow by 47% from 2020 to 2040. Moreover, the continuous investments in the biotechnology for the research and development programmes has resulted in the development of effective cancer treatment drugs. The growing adoption of technological advancements in the field of biopharmaceutical and rising consumer awareness regarding the safety of the targeted therapeutics is fueling the demand for the targeted therapeutics across the globe.
North America is the leading consumer of the targeted therapeutics owing to the increased adoption rate and higher demand for the advanced and innovative products. The rapidly booming biologics industry is a significant factor that propels the growth of the targeted therapeutics market in North America. Further, the presence of numerous CMOs and CROs along with the various biopharmaceutical companies together contributes towards the market development. Moreover, the rising geriatric population, increased disposable income, presence of high-end technologies and developed healthcare infrastructure, and rising demand for the biologic drugs is fueling the growth of the targeted therapeutics in North America.
Asia Pacific is estimated to be the most opportunistic market owing the presence of huge population and growing burden of diseases. The rising disposable income, rising awareness regarding advanced drugs and therapies, and rapidly growing healthcare infrastructure is expected to drive the targeted therapeutics market in the region. Moreover, the rapid penetration of pharmacies, especially the online pharmacies is expected to play a crucial role in the growth of the targeted therapeutics industry in the forthcoming years.
The market is driven by the rising prevalence of various types of cancer such as breast cancer, lungs cancer, colorectal cancer, and benign tumors. The increased efficiency of the targeted therapeutic drugs to treat such deadly diseases with minimal side effects is a major driving factor of the market.
However, the high cost associated with the targeted therapeutics may restrict the middle and low income people to opt for such expensive treatment, especially in the underdeveloped and developing economies. Further, lack of consumer awareness is another restraining factor that may hamper the market growth during the forecast period.
By type, the monoclonal antibodies segment was the leading segment in 2020 owing to its extensive use for the treatment of cancer. Further, its lower toxicity and minimal side effects has gained consumers’ confidence that boosted its adoption across the globe. On the other hand, the small molecule segment is expected to grow rapidly owing to is rising adoption in the treatment of malignancies.
By application, the lungs cancer segment dominated the market in 2020 owing to the increased cases of lungs cancer across the globe. This is the major reason for the increased demand for the targeted therapeutics to treat lungs cancer. Moreover, the breasts cancer segment is expected to flourish rapidly during the forecast period owing to the increased diagnosis of the breast cancer among the women population.
By distribution channel, the online pharmacies segment is expected to be the most opportunistic segment during the forecast period. The increased penetration of internet, rising adoption of digital devices, and rising popularity of online pharmacies among the consumers is boosting the growth of this segment.
Why should you invest in this report?
If you are aiming to enter the global targeted therapeutics market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for targeted therapeutics are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Some of the prominent players in the global targeted therapeutics market include:
- Pfizer, Inc.
- AstraZeneca Plc.
- Amgen, Inc.
- F. Hoffmann-La Roche & Co.
- Genentech, Inc.
- Agenus, Inc.
- Celdara Medical LLC
- Arcus Biosciences, Inc.
- Aurinia Pharmaceuticals Inc.
- Gilead Sciences, Inc.
- Serena Therapeutics Inc.
- Nektar Therapeutics Inc.
Market Segmentation:
By Type
- Monoclonal Antibodies
- Small Molecule
By Application
- Breast Cancer
- Colorectal Cancer
- Lung Cancer
- Renal Cancer
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Analysis:
The geographical analysis of the global targeted therapeutics market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American Market is again segmented into the US, Canada, and Mexico. Coming to the European Market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global targeted therapeutics Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global targeted therapeutics market in 2030?
- What is the expected CAGR for the targeted therapeutics market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global targeted therapeutics market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Targeted Therapeutics Market
5.1. COVID-19 Landscape: Targeted Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Targeted Therapeutics Market, By Type
8.1. Targeted Therapeutics Market, by Type, 2021-2030
8.1.1. Monoclonal Antibodies
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Small Molecule
8.1.2.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Targeted Therapeutics Market, By Application
9.1. Targeted Therapeutics Market, by Application, 2021-2030
9.1.1. Breast Cancer
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Colorectal Cancer
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Lung Cancer
9.1.3.1. Market Revenue and Forecast (2019-2030)
9.1.4. Renal Cancer
9.1.4.1. Market Revenue and Forecast (2019-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Targeted Therapeutics Market, By Distribution Channel
10.1. Targeted Therapeutics Market, by Distribution Channel, 2021-2030
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Forecast (2019-2030)
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Forecast (2019-2030)
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 11. Global Targeted Therapeutics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type (2019-2030)
11.1.2. Market Revenue and Forecast, by Application (2019-2030)
11.1.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type (2019-2030)
11.1.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.1.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type (2019-2030)
11.1.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.1.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type (2019-2030)
11.2.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type (2019-2030)
11.2.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type (2019-2030)
11.2.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type (2019-2030)
11.2.6.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type (2019-2030)
11.2.7.2. Market Revenue and Forecast, by Application (2019-2030)
11.2.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type (2019-2030)
11.3.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type (2019-2030)
11.3.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type (2019-2030)
11.3.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type (2019-2030)
11.3.6.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type (2019-2030)
11.3.7.2. Market Revenue and Forecast, by Application (2019-2030)
11.3.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type (2019-2030)
11.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type (2019-2030)
11.4.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type (2019-2030)
11.4.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type (2019-2030)
11.4.6.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.6.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type (2019-2030)
11.4.7.2. Market Revenue and Forecast, by Application (2019-2030)
11.4.7.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type (2019-2030)
11.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type (2019-2030)
11.5.4.2. Market Revenue and Forecast, by Application (2019-2030)
11.5.4.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type (2019-2030)
11.5.5.2. Market Revenue and Forecast, by Application (2019-2030)
11.5.5.3. Market Revenue and Forecast, by Distribution Channel (2019-2030)
Chapter 12. Company Profiles
12.1. Pfizer, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. AstraZeneca Plc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Amgen, Inc.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. F. Hoffmann-La Roche & Co.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Genentech, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Agenus, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Celdara Medical LLC
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Arcus Biosciences, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Aurinia Pharmaceuticals Inc.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Gilead Sciences, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
12.11. Serena Therapeutics Inc.
12.11.1. Company Overview
12.11.2. Product Offerings
12.11.3. Financial Performance
12.11.4. Recent Initiatives
12.12. Nektar Therapeutics Inc.
12.12.1. Company Overview
12.12.2. Product Offerings
12.12.3. Financial Performance
12.12.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1358
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
0 Comments